Larger Spot Sizes and Patented Cooling Device Make Treatments Faster, Easier and More Comfortable  

       Spa Noa is happy to announce the addition of Syneron’s GentleMax Pro laser hair removal system to the esthetics department of their Spa.

       Using Gentle Hair Removal™ technology, the GentleMax Pro laser powerfully, yet gently removes hair with faster treatment times and decreased sensation. Unlike many previous professional laser hair removal options, GentleMax Pro generates permanent outcomes and is safe and effective for all skin tones.

      Only Gentle Systems feature a patented Dynamic Cooling Device (DCD), which minimizes discomfort by releasing a quick
burst of liquid cryogen before and after each laser pulse. The cryogen rapidly evaporates, cooling the outer layers of the skin and making the treatment significantly more comfortable for patients by removing the snapping and burning generally associated with laser hair removal. During the treatment, a hand piece delivers a laser pulse into the targeted areas, and a controlled amount of therapeutic heat that safely and effectively damages the hair follicles.

“GentleMax Pro has redefined permanent hair removal for our Spa,” says co-owner, Lucy Silva. “The DCD technology makes treatments easy and comfortable for our clients, plus GentleMax Pro has the industry’s largest handpiece spot size of 24mm, allowing us to drastically reduce treatment time. Patients love the quicker treatments, plus it allows for greater efficiency and business growth in our spa.”

 

Adding to its value, GentleMax Pro is extremely versatile. It is not only FDA approved for permanent hair reduction, but also for treatment of a wide range of skin conditions including:

  • Hemangiomas

  • Rosacea

  • Beard Bumps (PFB)

  • Pigmented Lesions

  • Facial & Spider Veins

  • Leg Veins

  • Facial Redness

Hair removal treatments take anywhere from 
a few minutes to about an hour, depending on the area being treated. Since hair grows in three stages, four to six treatments spaced six weeks apart are recommended for optimal results.

Spa Noa is located at 11638 Plaza America, Reston, VA 20190 : or visit us at spanoa.com

 
About Syneron
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Company’s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Contacts:
Syneron – Public Relations
pr@syneron.com